A multi-center study to examine the pharmacokinetics, whole body and organ dosimetry, and biodistribution of fission-derived iodine I 131 tositumomab for patients with previously untreated or relapsed follicular or transformed follicular non-hodgkin's lymphoma

Trial Profile

A multi-center study to examine the pharmacokinetics, whole body and organ dosimetry, and biodistribution of fission-derived iodine I 131 tositumomab for patients with previously untreated or relapsed follicular or transformed follicular non-hodgkin's lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2008

At a glance

  • Drugs Iodine-131 tositumomab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top